Merck Alzheimer's drug fails in 1 study; another continues

Tuesday, 14 February 2017  (1 week ago)
*By The Canadian Press*

KENILWORTH, N.J. — Merck & Co. will stop its study of an experimental Alzheimer's drug in people with mild or moderate symptoms because interim results showed "virtually no chance" of any benefit.

However, the drugmaker said Tuesday it will continue another study of the drug, verubecestat, in...

Related Videos


Wochit News -   ▶  00:35

Advertisement

Recent related news

Advertisement
KENILWORTH, N.J. (AP) — Merck & Co. will stop its study of an experimental Alzheimer’s drug in people with mild or moderate symptoms because interim results...
1 week ago • Seattle Times
(Reuters) - Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel...
1 week ago • Reuters
Cigna says it is ending Anthem's proposed, $48-billion acquisition bid and seeking billions in damages from the Blue Cross-Blue Shield insurer. The announcement...
1 week ago • SeattlePI.com
(Reuters) - An experimental Merck & Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated...
2 hours ago • Reuters

You might like